Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fortigen
- Development stage
- Unknown
- Lead developer
- FRiLAB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Fortigen** is an oral fixed-dose syrup marketed by FRiLAB as an appetite stimulant and metabolic enhancer. Each 5 mL contains cyproheptadine hydrochloride 2 mg together with riboflavin, pyridoxine, thiamine, nicotinamide, and cyanocobalamin. Cyproheptadine is a first-generation antihistamine and antiserotonergic agent; its histamine- and serotonin-receptor antagonism is used in this product to support appetite stimulation, while the B vitamins provide nutritional supplementation. ([frilab.ch](https://www.frilab.ch/wp-content/uploads/2019/11/Fortigen-En.pdf))
- Brand names
- Fortigen
Beyond the preview
Go deeper on Fortigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fortigen.